Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Are me-too drugs justified?

S Garattini1

  • 1Mario Negri Institute for Pharmacological Research, Milano, Italy.

Journal of Nephrology
|January 27, 1998
PubMed
Summary

The pharmaceutical industry

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat.

Naunyn-Schmiedeberg's archives of pharmacology·1996
Same author

Pharmacology of ingestive behaviour.

Therapie·1996
Same author

DNA topoisomerase inhibitors.

Cancer chemotherapy and biological response modifiers·1996
Same author

Oral kinetics of dexfenfluramine and dexnorfenfluramine in non-human primates.

Xenobiotica; the fate of foreign compounds in biological systems·1995
Same author

Biological actions of drugs affecting serotonin and eating.

Obesity research·1995
Same author

Cultural shift in Italy's drug policy.

Lancet (London, England)·1995

Area of Science:

  • Pharmacology
  • Pharmaceutical industry
  • Drug development

Background:

  • The pharmaceutical industry, a multi-billion dollar market, increasingly prioritizes commercial interests over patient needs.
  • Drug development and marketing have adopted business rules, potentially compromising access to affordable medications.
  • Competition drives the development of "me-too drugs," which are chemically similar or have identical mechanisms of action to existing drugs.

Purpose of the Study:

  • To critically review the evidence supporting claims made by pharmaceutical firms for developing "me-too drugs."
  • To examine arguments justifying the creation of less innovative drugs.
  • To present data and examples of "me-too drugs" in the market.

Main Methods:

  • Literature review of scientific evidence.
  • Analysis of market trends and competition in the pharmaceutical sector.
  • Case study examples of "me-too drugs" and their justifications.

Main Results:

  • The paper will critically assess claims that "me-too drugs" offer improved efficacy, different adverse effect profiles, or better compliance.
  • Evidence regarding the cost-effectiveness and patient benefits of "me-too drugs" will be evaluated.
  • The study will provide figures and specific examples to illustrate the impact of "me-too drugs."

Conclusions:

  • The paper aims to provide a balanced perspective on the role and justification of "me-too drugs" in modern pharmacology.
  • Findings will inform healthcare providers and policymakers about the implications of pharmaceutical market dynamics.
  • A critical evaluation of "me-too drugs" is essential for ensuring patient access to effective and affordable treatments.

Related Experiment Videos